TNPO2

Across TCGA pan-cancer cohorts, TNPO2 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of TNPO2’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where TNPO2 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TNPO2 is over-expressed in tumor.

CCRCC, HNSC, and LSCC are the cancer types where TNPO2 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TNPO2 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	All	III,IV	+0.221	<.001	9	view →
HNSC	Male	II,III,IV	+0.189	<.001	8	view →
LSCC	Male	III,IV	+0.359	<.001	6	view →
PDAC	Male	All	+0.175	.010	3	view →
LUAD	Male	All	+0.096	.004	2	view →
COAD	Female	II,III,IV	+0.075	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

TNPO2–CCRCC

Open the CCRCC breakdown →